Phase III Trial Of Radical Chemo-radiation Vs Radiation Alone In The Management Of Localised Bladder TCC.
Funder
National Health and Medical Research Council
Funding Amount
$194,875.00
Summary
This trial aims to see if the combination of Chemotherapy and Radiation treatment is indeed superior in eradicating the tumor and preserving the Bladder in a greater number of patients as compared to Radiation treatment alone. If the final results from this study do show chemoradiotherapy to be significantly superior to radiation alone, without an increase in morbidity ( especially long term side effects ) , this may lay the platform for a greater proportion of patients with localised bladder ca ....This trial aims to see if the combination of Chemotherapy and Radiation treatment is indeed superior in eradicating the tumor and preserving the Bladder in a greater number of patients as compared to Radiation treatment alone. If the final results from this study do show chemoradiotherapy to be significantly superior to radiation alone, without an increase in morbidity ( especially long term side effects ) , this may lay the platform for a greater proportion of patients with localised bladder cancer, being in the first instance considered for this organ( bladder) preserving approach something which has become a reality at a number of other sites of cancer with the use of multimodality treatment.Read moreRead less
The spread of cancer to other organs is responsible for 90% of cancer deaths. This proposal seeks to determine how urological tumours (prostate and bladder) spread around the body. Cancer cell and animal models are an integral component of the research, and together with data obtained in human cancer specimens provide a comprehensive, powerful approach to identify key pathways involved in tumour spread. This is critical for the design of new therapies to treat and-or prevent tumour spread.
Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours
Funder
National Health and Medical Research Council
Funding Amount
$496,935.00
Summary
Chemoradiotherapy for oesophageal tumours has high interpatient variability in response and toxicity to treatment. Predictive biomarkers of response and toxicity would help select patients who would benefit most from this treatment modality. The proposed project will determine blood-derived microRNA and mRNA profiles that identify patients according to risk of unfavourable treatment outcomes, enabling clinicians to offer personalised alternative treatment strategies for those patients.
I am a medical oncologist and tumour immunologist, dedicated to basic and translational clinical research particularly in the field of urological cancer and also in melanoma.
Telomere Length As A Biomarker In Paediatric Cancers
Funder
National Health and Medical Research Council
Funding Amount
$121,025.00
Summary
Telomeres are the ends of chromosomes, and their length is important to maintain cell viability. We intend to set up a reliable test to measure telomere length and also use this measurement in childhood cancer patients to assess whether patients with shorter telomeres are more susceptible to the adverse effects of chemotherapy and radiotherapy.
Chemical And Structural Biology Validation Of Lamin B1 As A New Anti-cancer Target
Funder
National Health and Medical Research Council
Funding Amount
$638,272.00
Summary
The validation of new anti-cancer targets is critical for the development of new therapies. We have discovered a small molecule that disrupt the function Lamin B1 during cell division and decreases tumour growth significantly in vivo. With this research proposal, we will investigate the role that Lamin B1 exerts during cell division and why interfering with this protein has such a profound impact on cancer cells.
Methylation And The Risk Of Urothelial Cell Cancer
Funder
National Health and Medical Research Council
Funding Amount
$703,628.00
Summary
Why don’t we run prevention programs for urinary tract cancers like we do for others? It’s because we don’t know which lifestyle factors, except smoking, are important to cancers of the renal pelvis, ureters, bladder and urethra. We plan to use new technology to measure the ‘epigenome’, the part of the genome that turns genes on or off. This may explain how lifestyle factors influence what genes do, and we hope our findings will help to develop future prevention strategies for these cancers.
A Multi-Centre Feasibility Study Of Online Adaptive Image Guided Radiotherapy For Muscle Invasive Bladder Cancer
Funder
National Health and Medical Research Council
Funding Amount
$580,152.00
Summary
Many studies have shown that the bladder can move, change in size and shape through a course of radiation therapy. As shown in a pilot study, with the online adaptive radiotherapy technique trained staff can daily match the radiation fields to the bladder position and size using a type of CT scan. Potential benefits are better cancer coverage with improved cancer control and less normal tissue irradiation. This study will determine if the technique will work across multiple Australian centres.